Advicenne reports its First Half Financial results as of June 30, 2022

Paris - Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, today reports its semi-annual financial results as of June 30, 2022, as approved on September 20, 2022 by the Board of Directors.

The semi-annual financial report is available on the Company's website: www.advicenne.com.

Didier Laurens, Chief Executive Officer of Advicenne, highlighted: 'If during the first half of 2022 we completed the operational rationalization of Advicenne through the consolidation of all our activities in one single premise in Paris with immediate impact on our cash consumption, the period was mostly remarkable for Sibnayal's progress. We are particularly satisfied with the 15% increase in sales reported and achieved prior to any commercial effort, which marks Sibnayal's added value to prescribers and patients. With more than 75 hospitals already ordering Sibnayal in Europe, we expect sales to significantly accelerate in the second half with the geographic expansion of sales for which we work closely with our partners. Our ambition is to make Sibnayal available to the largest number of patients and obtain the best conditions for registration, prices and reimbursement. The second half should mark a further acceleration of our flagship product given its entry into new territories. In terms of funding, we estimate our financial visibility through the third quarter of 2023, based on our cash and outlook.'

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022.

Contact:

Didier Laurens

Tel: [phone]

Email: [e-mail]

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2021 Universal Registration Document filed with the French financial market authority on April 29, 2022 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets, and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.

(C) 2022 Electronic News Publishing, source ENP Newswire